News for Keros Therapeutics, Inc. (KROS)

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 4% on Thursday. The Dow traded down 4.18% to 38,910.71 while the NA...

U.S. stocks were lower, with the Dow Jones index dipping over 800 points on Thursday. Shares of PriceSmart, Inc. PSMT rose sharply during Thursday's session fo...

Denver-based InnovAge Holding Corp (INNV) is up over 58 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

**media[581131]**

The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (”œKeros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused

Revenue: $3.0 million for Q4 2024, significantly below the estimated $15.42 million.Net Loss: $46.0 million for Q4 2024, compared to $40.2 million in Q4 2023,

Keros Therapeutics (KROS) delivered earnings and revenue surprises of -22.58% and 97.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (”œKeros” or the ”œCompany”) ( KROS), a clinical-stage biopharmaceutical co

**media[551523]**

Significant Reduction in Keros Therapeutics Holdings On December 31, 2024, ALKEON CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a notable reduction in its

On December 31, 2024, Darwin Global Management, Ltd. (Trades, Portfolio) executed a significant transaction involving Insmed Inc., a global biopharmaceutical co

On January 31, 2025, FMR LLC (Trades, Portfolio) executed a significant transaction involving Keros Therapeutics Inc. (NASDAQ: KROS), reducing its holdings by 4

KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.

Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Keros Therapeutics (KROS) stock rises as a licensing deal with Takeda (TAK) begins. However, Cantor Fitzgerald downgrades, citing a trial setback. Read more here.

Keros stock climbs on Takeda deal effectiveness